Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Bought by MetLife Investment Management LLC

MetLife Investment Management LLC grew its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 2.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 92,734 shares of the biopharmaceutical company’s stock after purchasing an additional 2,454 shares during the quarter. MetLife Investment Management LLC owned approximately 0.06% of Ocular Therapeutix worth $792,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the stock. First Trust Advisors LP acquired a new position in shares of Ocular Therapeutix in the fourth quarter worth $1,819,000. CANADA LIFE ASSURANCE Co raised its stake in Ocular Therapeutix by 152.4% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 30,227 shares of the biopharmaceutical company’s stock valued at $258,000 after purchasing an additional 18,251 shares during the last quarter. Walleye Capital LLC purchased a new position in Ocular Therapeutix in the 4th quarter valued at about $90,000. XTX Topco Ltd acquired a new stake in shares of Ocular Therapeutix during the 4th quarter worth about $99,000. Finally, Raymond James Financial Inc. purchased a new stake in shares of Ocular Therapeutix during the fourth quarter worth about $1,722,000. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix Price Performance

Ocular Therapeutix stock opened at $8.80 on Friday. The company has a quick ratio of 12.94, a current ratio of 13.01 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $1.40 billion, a P/E ratio of -6.67 and a beta of 1.51. The firm has a fifty day moving average of $7.40 and a 200-day moving average of $8.41. Ocular Therapeutix, Inc. has a 52-week low of $4.79 and a 52-week high of $11.78.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The company had revenue of $17.08 million during the quarter, compared to analysts’ expectations of $16.89 million. As a group, analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Wall Street Analysts Forecast Growth

OCUL has been the topic of several recent analyst reports. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They set an “outperform” rating and a $17.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. William Blair initiated coverage on Ocular Therapeutix in a report on Tuesday, April 8th. They issued an “outperform” rating for the company. JMP Securities set a $19.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $16.38.

Insiders Place Their Bets

In other news, insider Pravin Dugel sold 21,475 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the transaction, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Donald Notman sold 11,119 shares of the business’s stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total transaction of $86,839.39. Following the completion of the transaction, the insider now owns 193,444 shares in the company, valued at $1,510,797.64. This represents a 5.44 % decrease in their position. The disclosure for this sale can be found here. 3.50% of the stock is owned by company insiders.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.